Greetings everyone,

Below is a nice update from iCo Therapeutics Investor Relations.

What is great is that iCo will be presenting at the JP Morgan Healthcare Conference and I believe with their US listing (ICOTF) along with results being only 2 to 3 months away, this could be another great attention event.

On Friday the stock traded 1.1 million shares of which 448k+ were from the US and we broke the 50 cent mental barrier closing up 17%. Technically we have no major resistance till early 70's. Of course, this will not happen over night, but the way we are trading can tell that we will be heading there in the coming short while.

Good luck with your investment,
MMN


Subject: The Biotech Bull continues...
Date: Fri, 10 Jan 2014 09:43:35 -0800

The US Health Care and Biotech Market is continuing its tear with Intercept (NASDAQ: ICPT) announcing yesterday that they are stopping their Phase II trial early because the trial showed overwhelming efficacy data based on an interim analysis of the primary end point. The 283 patient, US based, multicenter Phase II trial is evaluating a treatment for non-alcoholic steatohepatitis (liver inflammation / fatty liver). The stock is up 370% since the announcement yesterday.



Our investment, ICO Therapeutics (TSX-V: ICO, OTCQX: ICOTF) will be reporting Phase II efficacy data from their own +180 patient, US based, multicenter Phase II trial for the treatment of Diabetic Macular Edema sometime in March/April 2014. The company recently listed on the OTCQ-X and has spent much of the past few years marketing the story in the US. We are seeing an inflow of interest already from the US and expect it to continue as the company gets set to report the single largest milestone in its history.



Next week the company will be attending the JP Morgan Healthcare Conference in San Francisco - Always a hotbed of investment and partnership activity.



--

Thanks and Best Regards,



Kyle Boyko